Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.19 USD | +0.81% | +3.19% | -9.81% |
Business Summary
Number of employees: 344
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gene Therapy
100.0
%
| 113 | 100.0 % | 90 | 100.0 % | -19.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
68.0
%
| 62 | 55.0 % | 61 | 68.0 % | -1.02% |
United States
32.0
%
| 39 | 35.0 % | 29 | 32.0 % | -26.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
Chief Tech/Sci/R&D Officer | - | 15-10-31 | |
Olivier Danos
CTO | Chief Tech/Sci/R&D Officer | 66 | 17-03-27 |
Stephen Pakola
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-04-16 |
Curran Simpson
COO | Chief Operating Officer | 62 | 15-07-31 |
Shiva G. Fritsch
IRO | Public Communications Contact | - | 16-12-31 |
Laura Coruzzi
PRN | Corporate Officer/Principal | 71 | - |
Ram Palanki
PRN | Corporate Officer/Principal | 48 | 18-07-31 |
General Counsel | 53 | 16-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
Director/Board Member | 71 | 15-04-30 | |
Daniel Tassé
BRD | Director/Board Member | 64 | 16-08-14 |
Director/Board Member | 65 | 18-05-24 | |
Allan Fox
CHM | Chairman | 76 | 08-12-31 |
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Jennifer Zachary
BRD | Director/Board Member | 46 | 22-06-02 |
Jean Bennett
BRD | Director/Board Member | 69 | 21-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,042,717 | 45,180,406 ( 92.12 %) | 0 | 92.12 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.81% | 794M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RGNX Stock
- Company REGENXBIO Inc.